OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms. Read more about OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms.
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. Read more about Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
KIT expression and methylation in medulloblastoma and PNET cell lines and tumors. Read more about KIT expression and methylation in medulloblastoma and PNET cell lines and tumors.
FACT-MNG: tumor site specific web-based outcome instrument for meningioma patients. Read more about FACT-MNG: tumor site specific web-based outcome instrument for meningioma patients.
Pathological classification and molecular genetics of meningiomas. Read more about Pathological classification and molecular genetics of meningiomas.
Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. Read more about Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study.
Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. Read more about Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update.
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. Read more about High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.
